Immunotherapy for penile cancer

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology Pub Date : 2024-08-09 DOI:10.1038/s41585-024-00932-5

Louise Lloyd

引用次数: 0

查看原文本刊更多论文

阴茎癌免疫疗法

单药瑞替凡利单抗在晚期和转移性阴茎鳞状细胞癌中显示出良好的临床活性，且没有出现新的安全信号。客观反应率为16.7%，3名患者获得部分反应。中位无进展生存期为2.0个月，中位总生存期为7.2个月。一名患者出现了 3 级治疗相关不良事件。这项ORPHEUS II期研究的结果为进一步研究retifanlimab治疗阴茎癌提供了依据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Urology 医学-泌尿学与肾脏学

CiteScore

12.50

自引率

2.60%

发文量

123

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.